This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human TrkB / NTRK2 (rh TrkB / NTRK2, NP_001007098.1, Met1-His430) and conjugated with PE under optimum conditions, the unreacted PE was removed.
TrkB is a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor exclusively expressed in neurons of the central nervous system. BDNF (brain-derived neurotrophic factor) exerts biological actions through its physiological receptor TrkB which leads to the initiation of intracellular signaling cascades and different biological responses in neurons. TRKB has two distinct binding regions for BDNF within the extracellular domain with high affinity. Upon neurotrophin binding, TrkB phosphorylates itself and the downstream molecular members of the related signal pathways. TrkB has been shown to play an important role in tumorigenesis and metastasis, and mutations in this gene are associated with obesity and mood disorders. Accordingly, BDNF/TrkB signaling is thought to be a potential therapeutic target for schizophrenia.